[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"binder-type-list":3},[4,15,25,34,43],{"id":5,"binderType":6,"binderTypeShort":7,"description":8,"introduction":9,"targets":10,"mice":11,"pic":12,"icon":13,"gpcr":14},1,"All Binder Types","All","Biocytogen's comprehensive, fully human antibody portfolio spans diverse binder formats. We support a wide range of discovery needs—from high-affinity monoclonals and plug-and-play bispecific formats to compact VHH molecules with deep tissue penetration, as well as antibodies targeting hard-to-drug GPCRs and other challenging targets.","\u003Cp>Biocytogen's comprehensive, fully human antibody portfolio spans diverse binder formats. We support a wide range of discovery needs—from high-affinity monoclonals and plug-and-play bispecific formats to compact VHH molecules with deep tissue penetration, as well as antibodies targeting hard-to-drug GPCRs and other challenging targets.\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>","CDH6,LY6G6D,ASGR1","RM,RL,RN","https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002F20251204\u002FRectangle 22166 (1)_1764826504142.png","https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002F20251219\u002FAll-Binder-Types_1766123391962.png",0,{"id":16,"binderType":17,"binderTypeShort":18,"description":19,"introduction":20,"targets":21,"mice":22,"pic":23,"icon":24,"gpcr":14},5,"Regular Monoclonal Antibody","mAb","Monoclonal antibodies generated from RenMab mice offer high diversity and affinity, require no humanization, and are widely used across oncology, autoimmune, metabolic, and other therapeutic areas.","\u003Cp>Monoclonal antibodies generated from RenMab mice offer high diversity and affinity, require no humanization, and are widely used across oncology, autoimmune, metabolic, and other therapeutic areas.\u003C\u002Fp>","C5a,ALPL","RM","https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002F20251204\u002FRectangle 22166 (4)_1764826375633.png","https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002F20251211\u002FRegular monoclonal_1765452416165.png",{"id":26,"binderType":27,"binderTypeShort":18,"description":28,"introduction":29,"targets":30,"mice":31,"pic":32,"icon":33,"gpcr":14},3,"Common Light Chain Antibody","Common light chain antibodies share a single light chain, preventing heavy–light chain mispairing and simplifying bispecific assembly to near-monoclonal efficiency. Biocytogen has developed antibody scaffolds covering 200+ TAA targets, enabling plug-and-play rapid screening and validation of bispecific antibodies and bispecific ADC therapies.","\u003Cp>Common light chain antibodies share a single light chain, preventing heavy–light chain mispairing and simplifying bispecific assembly to near-monoclonal efficiency. Biocytogen has developed antibody scaffolds covering 200+ TAA targets, enabling plug-and-play rapid screening and validation of bispecific antibodies and bispecific ADC therapies.\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>","ALPL,CDH6","RL","https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002F20251204\u002FRectangle 22165_1764826334087.png","https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002F20251211\u002FCommon light chain_1765452431647.png",{"id":35,"binderType":36,"binderTypeShort":37,"description":38,"introduction":39,"targets":21,"mice":40,"pic":41,"icon":42,"gpcr":14},24,"HCAb\u002FVHH Antibody;VHH","VHH","VHH antibodies are compact, stable, and highly penetrant, enabling efficient delivery into tumors and across the blood–brain barrier. Their simple architecture reduces manufacturing complexity, making them ideal components for bispecific antibodies, multispecific formats, and cell therapies.","\u003Cp>VHH antibodies are compact, stable, and highly penetrant, enabling efficient delivery into tumors and across the blood–brain barrier. Their simple architecture reduces manufacturing complexity, making them ideal components for bispecific antibodies, multispecific formats, and cell therapies.\u003C\u002Fp>","RN","https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002F20251204\u002FRectangle 22166 (3)_1764827779193.png","https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002F20251211\u002FVHH_1765452404025.png",{"id":44,"binderType":45,"binderTypeShort":46,"description":47,"introduction":48,"targets":30,"mice":49,"pic":50,"icon":51,"gpcr":5},2,"Anti-GPCR Antibody","","GPCR-targeting antibodies can modulate signaling pathways and eliminate diseased cells via ADCC\u002FADCP. However, GPCRs have historically been challenging to drug with antibodies. Leveraging our proprietary RenMice® technology, Biocytogen delivers high-affinity, high-specificity human GPCR antibodies—including mono- and bispecific formats—to advance oncology and metabolic therapies.","\u003Cp>GPCR-targeting antibodies can modulate signaling pathways and eliminate diseased cells via ADCC\u002FADCP. However, GPCRs have historically been challenging to drug with antibodies. Leveraging our proprietary RenMice® technology, Biocytogen delivers high-affinity, high-specificity human GPCR antibodies—including mono- and bispecific formats—to advance oncology and metabolic therapies.\u003C\u002Fp>","RL,RN","https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002F20251204\u002FRectangle 22166_1764826434296.png","https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002F20251211\u002FGPCR_1765452438618.png"]